ClinicalTrials.govpublic full text
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
acute myeloid leukemia (aml), flt3-itd mutation, allogeneic hematopoietic cell transplantation (hct), maintenance therapy, gilteritinib, sorafenib, acute myeloid leukemia, allogeneic hematopoietic cell transplantatio, sorafeni, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1044966
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.